AlphaBeta Pharmaceutical

Ofni Systems Inc. FDA Facsimile Approval: 03/22/06

U.S. Department of Health and Human Services Food and Drug Administration

For use by user-facilities, importers, distributors and manufacturers for MANDATORY reporting

		FDA Use Only
JF/Importer Report		
Mfr Report	AA 2255	

MEDWATCH

				Page	of			FDA Use Only	
A. PATIENT INF	FORMATION				C. SUSPECT PRO	ODUCT(S)			
1. Patient Identifie	Identifie 2. Age at Time of Event:		3. Sex	4. Weight	1. Nam (Give labeled s	, ,			
9182 or 30		✓ Female	<u>125</u> lbs	#1 Axaprienette, 200mg, AlphaBeta Pharmaceutical					
In confidence	Date Of Birth:		Male	or kgs	#2				
		CT PROBLE	· M		2. Dose, Frequency & I	Route Use	3. Therapy Da	te (If unknown, give duration, best estimate)	
B. ADVERSE EVENT OR PRODUCT PROBLE 1. Adverse Event and/or Product Problem (e)		.g. defects/malfunctions)		#1 400mg, every 4 hours, oral		#1 1/1/2006 to 2/1/2006			
	ted to Adverse Event	ice i robiciii (e.	.g. derees, man	unctionsy	#2		#2		
(Check all that apply					4. Diagnosis for Us (I	indication)		Event Abated After Use	
Death:	Death: Disability or		Permanent Damage		#1 Low alpha waves		Stopped or Dose #1 Yes No Doesn't		
✓ Life-Threatening	Life-Threatening Congenital		Anomaly/Birth Defect		#2		Apply		
✓ Hospitalization -		_	us (Important M		6. Lot	7. Exp. Dat	#2	? Yes No Doesn't	
	ention to Prevent Permane		'		#1 63A441	#1 6/1/200	8.	Event Reappeared After	
3. Date of Event (m 2/1	nm/dd/yyyy) 1/2006	4. Date of Thi	is Report <i>(mn</i> 2/15/2006		#2	#2		Reintroduction ✓ Yes No Doesn't	
5. Describe Event or	•				9. NDC# or Unique ID	· ·		Apply Describ	
The patient disp	layed discoloration	of the skin o	n the upper	half of	312337.221		#2	Yes No Doesn't Apply	
	nutes after beginnin				10. Concomitant Medic	cal Products and Th	erapy Dates (Exclude treatment of event)	
	nal distress with inte d completely disapp				Irqplacebo, 1/26/2	.006			
, ,	eappear at irregular		or oximiacely						
					D. SUSPECT ME	DICAL DEVICE			
					1. Brand Name				
					2. Common Device Name				
					3. Manufacturer Name, City and State				
					5. Manufacturer Name	, city and State			
					4. Model	Lot #		5. Operator of Device Health Profession	
					Catalog #	Expiration	Expiration Date (mm/dd/yyyy) Lay User Other		
					Serial	Other		Oulei	
					6. If Implanted, Give D	Date (mm/dd/yyyy)	7. If Explant	ed, Give Date (mm/dd/yyyy)	
_	aboratory Data, Includi	ng Dates			8. Is this a Single-use	Device that was Re	processed and	Reused on a Patient?	
EEG, negative, 2 BA, .035, 2/1/20					Yes No				
,, , , .					9. If Yes to Item No. 8	, Enter Name and A	ddress of Repr	ocessor	
				10. Device Available for Evaluation? (Do not send to FDA)					
					Yes No Returned to Manufacturer on: (mm/dd/yyyy				
					11. Concomitant Medic	cal Products and Th	erapy Dat (Exc	clude treatment of event)	
	istory, Including Preex moking and alcohol use, h			e.g. allergies,					
., 5 ,,	al breeds of cats (T		, ,						
Sensitivity to light and low decibal noise after co		,,	, , ,		E. INITIAL REPO				
				1. Name and Address	Phon	Phone (919) 555-9292 ext. 13			
					Charles Brown	L			
					Chief Examiner				
					1234 Main Street Suite 1000				
					Raleigh, NC 2979	9-1234			
Submission of a re	eport does not cons	titute an adn	nission that		2. Health Professional			4. Initial Reporter Also Ser	
medical personne	el, user facility, impo	rter, distribu	itor,		Yes No	Registered Nu	ırse	Report to FDA Yes No V Unk.	

medical personnel, user facility, importer, distributor, manufacturer or product caused or contributed to the event.

MEDWATCH 3500A Facsimile (3/06) (continued) Page of H. DEVICE MANUFACTURERS ONLY F. FOR USE BY USER FACILITY/IMPORTER (Devices only) 1. Check One 1. Type of Reportable Event 2. If Follow-up, What Type? 2. UF/Importer Report Number **✓** User Facility Importer Death Correction 3. User Facility or Importer Name/Addre Serious Injury Additional Information Malfunction Response to FDA Request Other Device Evaluation 4. Device Manufacture Date (mm/dd/yyyy) 3. Device Evaluated by Manufacturer? Not Returned to Manufacturer Yes Evaluation Summary Attached 4. Contact Person 5. Phone Number 5. Labeled for Single Use? No (Attach page to explain why not) or provide code 6. Date User Facility or 7. Type of Report 8. Date of This Report Yes No Importer Became (mm/dd/yyyy) Initial Aware of Event (mm/dd/yyyy) Follow-up 6. Evaluation Code (Refer to coding manual) Method 9. Approximate 10. Event Problem Codes (Refer to coding manual) Age of Device Patient Results Code Device Conclusions Code 12. Location Where Event Occurred 11. Report Sent to FDA 7. If Remedial Action Initiated, Check Type 8. Usage of Device Hospital Outpatient Initial Use of Device Yes Recall Notification Diagnostic Facility Home (mm/dd/yyyy) Repair Reuse Inspection No Ambulatory Nursing Hom Surgical Facility Unknown Replace Patient Monitoring 13. Report Sent to Manufacturer 9. If action reported to FDA under Outpatient Relabeling Modification/ ___ Yes 21 USC 360i(f), list correction/ Treatment Facility Adjustment (mm/dd/yyyy) removal reporting number: Other No Other (Specify 14. Manufacturer Name/Address 10. Additional Manufacturer Narrative and/or 11. Corrected Data **G. ALL MANUFACTURERS** Contact Office - Name/Address (and Manufacturing 2. Phone Number Site for Devices) (919) 555-2345 ex AlphaBeta Pharmaceutical LLC 3. Report Source 9999 Highway 77 West (Check all that apply) Building 550 Foreign Morrisville, NC 27999-3456 Study USA Literature Consumer ✓ Health Professional 4. Date Received ✓ User Facility by Manufacture(mm/dd/yyyy) (A)NDA # <u>5633</u> Company 2/5/2006 Representative IND# 6. If IND, Give Protocol # Distributor STN # Other: 7. Type of Report 510(k) # 442 (Check all that apply) Combination **✓** 5-Day 30-Day

The public reporting burden for this collection of information has been estimated to average 66 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Product

Pre-1938

OTC Produc Yes

8. Adverse Event Term(s)

7-Day Periodic

____ 15-Day ____ Follow-up # 9. Manufacturer Report Number

___ 10-Day ___ Initial

AA 2255

✓ Yes

Yes

Bluecircle alteration, unsound striation

Department of Health and Human Services Food and Drug Administration 10903 New Hampshire Avenue Building 22, Mail Stop 4447 Silver Spring, MD 20993-0002

OMB Statement

"An agence may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.'